Agricultural compositions are disclosed which comprise at least one isolated bacteriophage capable of infecting the plant pathogen Pseudomonas syringae pv. tomato, the at least one bacteriophage having a genomic nucleic acid sequence at least 85% identical to one of the nucleic acid sequence as set forth in SEQ ID NOs: 1-23. The composition comprises no more than 10 different strains of bacteriophage. Uses thereof for treating bacterial speck disease are also disclosed.

Provided is a novel bacteriophage CJ23 (KCCM11365P). In addition, the present invention relates to an antibacterial composition including the bacteriophage CJ23 (KCCM11365P) as an active ingredient. Further, provided is a method of preventing and/or treating infectious diseases by avian pathogenic Escherichia coli (APEC) in birds using the bacteriophage CJ23 (KCCM11365P) or the antibacterial composition containing the bacteriophage CJ23 (KCCM11365P) as an active ingredient.

Disclosed herein are methods and systems for rapid detection of microorganisms such as Cronobacter spp. in a sample. A genetically modified bacteriophage is also disclosed which comprises an indicator gene in the late gene region. The specificity of the bacteriophage, such as Cronobacter-specific bacteriophage, allows detection of a specific microorganism, such as Cronobacter spp. and an indicator signal may be amplified to optimize assay sensitivity.

The present invention relates to bacteriophage therapy. More particularly, the present invention relates to novel bacteriophages having a high specificity against Escherichia coli strains, their manufacture, components thereof, compositions comprising the same and the uses thereof in phage therapy.

The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of P. aeruginosa. Treatment in this context may be either therapeutic or prophylactic treatment. Also provided are deposited bacteriophages each exhibiting different strain specificity against P. aeruginosa and combinations of such bacteriophages, e.g. a panel of six deposited bacteriophages which was found to be effective against a high percentage of clinical isolates of P. aeruginosa from canine ear infections.

The present disclosure provides a phage for lysing Burkholderia gladioli and use thereof, and belongs to the technical field of phages. The phage for lysing Burkholderia gladioli provided by the present disclosure is Burkholderia gladioli phage vB_BglM_WTB with an accession number of CCTCC M 2023525, which is a novel phage. The phage provided by the present disclosure has a strong lytic effect on the Burkholderia gladioli with higher temperature tolerance and wider acid-base tolerance range and effectively kills the Burkholderia gladioli on food surface, providing a new strategy for controlling the Burkholderia gladioli in food processing and environment.

In alternative embodiments, provided are products of manufacture and kits, and methods, to enrich for and/or isolate microbes such as viruses and/or phages capable of targeting, e.g., binding to, targeting, and/or killing or otherwise making non-viable or non-pathogenic, specific or desired microbes such as bacteria. In alternative embodiments, provided are products of manufacture comprising: a virus and/or a phage (a bacteriophage). In alternative embodiments, provided are products of manufacture and kits containing a virus and/or a phage (a bacteriophage) enriched for, selected for or isolated by a method as provided herein, or a microbe containing a virus and/or a phage (a bacteriophage) enriched, selected for and/or isolated by a method as provided herein.

The present invention provides a simple culture device that is designed for manufacture and use in areas of limited resources. The device is useful for cell culture in such environments with limited resources because cells grow in paper just as they do in a culture dish. Also provided is a binding assay that employs an activatable dormant bacteriophage carrying a reporter gene to qualitatively or quantitatively detect the presence of a substance of interest in a sample.

The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of P. aeruginosa. Treatment in this context may be either therapeutic or prophylactic treatment. Also provided are deposited bacteriophages each exhibiting different strain specificity against P. aeruginosa and combinations of such bacteriophages, e.g. a panel of six deposited bacteriophages which was found to be effective against a high percentage of clinical isolates of P. aeruginosa from canine ear infections.

Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.